Alnylam Pharmaceuticals (ALNY) Capital Expenditures (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Capital Expenditures data on file, last reported at $21.8 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 143.4% year-over-year to $21.8 million; the trailing twelve-month figure through Mar 2026 stood at $71.6 million (up 74.52% YoY), and the FY2025 full-year result was $58.7 million, up 71.24% from the prior year.
• Capital Expenditures for Q1 2026 stood at $21.8 million, down from $23.3 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $31.3 million in Q3 2025 and bottomed at -$45.2 million in Q4 2022.
• The 5-year median for Capital Expenditures is $15.3 million (2023), against an average of $10.7 million.
• Peak annual rise in Capital Expenditures reached 300.09% in 2025, while the deepest fall reached 314.67% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$45.2 million in 2022, then soared by 133.86% to $15.3 million in 2023, then tumbled by 40.6% to $9.1 million in 2024, then surged by 156.12% to $23.3 million in 2025, then retreated by 6.26% to $21.8 million in 2026.
• The last three Capital Expenditures figures came in at $21.8 million (Q1 2026), $23.3 million (Q4 2025), and $31.3 million (Q3 2025), per Business Quant data.

Peer Comparison